A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with MET-overexpressing NSCLC Meeting Abstract
| Authors: | Drilon, A.; Awad, M. M.; Camidge, D. R.; Forde, P. M.; Alexander, M.; Gadgeel, S. M.; Villaruz, L. C.; Perez, J.; Navas, T.; Daly, C.; Patel, S.; Li, S.; Laughlin, M.; Lowy, I.; Magnan, H.; Rietschel, P. |
| Abstract Title: | A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with MET-overexpressing NSCLC |
| Meeting Title: | 2023 World Conference on Lung Cancer (IASLC-WCLC) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 18 |
| Issue: | 11 Suppl. |
| Meeting Dates: | 2023 Sep 9-11 |
| Meeting Location: | Singapore |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-11-01 |
| Start Page: | S602 |
| End Page: | S603 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2023.09.1136 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: EP10.01-03 -- Source: Cinahl |
